Fennec CCO receives 168 shares at zero cost

FENNEC PHARMACEUTICALS INC.

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. (FENC) reported an insider equity change by Chief Commercial Officer Terry L. Evans. On 2026-08-31, Evans acquired 168 Common Shares at a reported price of $0.00 per share, reflecting shares released from restriction related to an award originally granted on 2025-03-28. Following this release, Evans directly holds 21,519 Common Shares of Fennec Pharmaceuticals Inc.

Insider Trade Summary

Grant/Award: 168 shares

Grant/Award 1 txn

Insider Evans Terry L

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	168	$0.00	$0.00

Holdings After Transaction: Common Shares — 21,519 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 3/28/2025.

Key Figures

Shares acquired: 168 Common Shares Transaction price per share: $0.00 Total shares following transaction: 21,519 Common Shares

3 metrics

Shares acquired 168 Common Shares Released from restriction on 2026-08-31 from shares awarded 2025-03-28

Transaction price per share $0.00 Reported for the 168 Common Shares released from restriction

Total shares following transaction 21,519 Common Shares Direct holdings of Terry L. Evans after the 2026-08-31 release

Key Terms

Common Shares, shares released from restriction, Grant, award, or other acquisition

3 terms

Common Shares financial

"The security involved in the transaction is described as Common Shares."

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

Grant, award, or other acquisition financial

"The transaction code description is Grant, award, or other acquisition."

FAQ

What insider transaction did FENC disclose for Terry L. Evans?

Fennec Pharmaceuticals Inc. disclosed that Chief Commercial Officer Terry L. Evans acquired 168 Common Shares on 2026-08-31, representing shares released from restriction from a prior equity award granted on 2025-03-28.

How many FENC shares does Terry L. Evans own after this transaction?

After the 168-share release, Chief Commercial Officer Terry L. Evans directly holds 21,519 Common Shares of Fennec Pharmaceuticals Inc., as reported in the Form 4 filing.

Was cash paid for the FENC shares acquired by Terry L. Evans?

The filing reports a transaction price of $0.00 per share for the 168 Fennec Pharmaceuticals Inc. Common Shares, indicating the shares were received as part of an equity award release rather than a market purchase.

What is the nature of the FENC shares acquired by Terry L. Evans?

The 168 Fennec Pharmaceuticals Inc. Common Shares represent shares released from restriction tied to shares originally awarded on 2025-03-28, according to the transaction footnote.

Is this FENC insider transaction part of a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and the footnotes do not state that the 168-share release was effected under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 08:14 PM Accepted by SEC EDGAR 08/31/2026 - 08:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Evans Terry L

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	08/31/2026		A		168	A	$0	21,519	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Terry Evans	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)